A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial
to be conducted in 2 sequential parts:
- Part A (Dose Escalation) in subjects with advanced malignancies
- Part B (Dose Confirmation) in subjects with tumor type(s) to be determined by results of
Part A